Shopping Cart

The shopping cart is empty

View courses and libraries and add them to the cart

{{item.title}} {{item.ceu}} hour {{item.ceu}} hours {{item.price | currency}} {{ getItemDiscountedPrice(item.price, item.discountedAmount) | currency}} {{item.priceAdjusted | currency}}

{{item.title}} {{item.price | currency}} {{ getItemDiscountedPrice(item.price, item.discountedAmount) | currency}} {{item.priceAdjusted | currency}}

Customers who Purchased
this Activity also Purchased

PREMIUM

{{recommendationsA.Title}}

Article
{{recommendationsA.Ceu}} hour | {{recommendationsA.Price | currency}} Article
{{recommendationsA.Ceu}} hours | {{recommendationsA.Price | currency}} {{recommendationsA.Price | currency}}

{{recommendationsA.Type}} {{recommendationsA.Type}}

PREMIUM

{{recommendationsB.Title}}

Article
{{recommendationsB.Ceu}} hour | {{recommendationsB.Price | currency}} Article
{{recommendationsB.Ceu}} hours | {{recommendationsB.Price | currency}} {{recommendationsA.Price | currency}}

{{recommendationsB.Type}} {{recommendationsB.Type}}

Total

{{totalCEUs}} hour{{totalCEUs}} hours

{{cart.total_amount | currency}}

@media (max-width: 991px) { body { padding-top: 0; } .site-header { height: auto; min-height: 65px; } .site-header.fixed-top { position: relative; } .site-header .container-fluid { flex-flow: row wrap; } .nav-site-toggle { display: none; } .site-logo { position: static; top:auto; left:auto; transform: none; margin: 10px auto; order: 1; } .nav-site { width: 100%; position: static; overflow: visible; background-color: #ffffff; order: 3; } .nav-site-close { display: none; } .nav-site .nav-site-menu { width: 100%; height: auto; margin-left: 0; overflow: visible; } .nav-site .nav-item .dropdown-toggle::after{ display: none; } .nav-site .navbar-nav { margin: 0; padding: 0; position: relative; overflow: visible; overflow-y: visible; height: auto; } .nav-site .nav-breadcrumb { display: none; } .nav-site .nav-item .dropdown-toggle { background-color: #e1e1e1; text-transform: uppercase; } .nav-site .nav-item .dropdown-menu { position: static; margin: 0; } .nav-site .nav-site-menu .navbar-nav .nav-item.dropdown-resources { font-weight: bold; background-color: #F2F4F6; } .nav-user { order: 2; margin: 0 10px 10px 10px; width: 100%; text-align: center; } .nav-user .user-menu { flex-flow: row wrap; } .nav-user .user-menu .user-menu-toggle { } .nav-user .user-menu .dropdown-menu { display: block; width: 100% !important; position: static; float: none; } .nav-user .user-menu .dropdown-menu::before, .nav-user .user-menu .dropdown-menu::after { display: none; } } @media (min-width: 992px) { body { padding-top: 0; } .site-header { height: auto; min-height: 65px; margin-bottom: 500px; } .site-header.fixed-top { position: static; } .nav-site .nav-site-menu .navbar-nav .nav-item:hover > .dropdown-menu { display: block; position: absolute; } .nav-site .nav-site-menu .navbar-nav .nav-item:focus-within > .dropdown-menu { display: block; position: absolute; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu { display: block; position: absolute; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu.super { display: flex; flex-flow: row nowrap; position: absolute; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu.sm1 { left: -376%; padding-right: 20px; width: 548px; } .nav-site .nav-site-menu .navbar-nav .nav-item > .dropdown-menu.sm1:before { left: 80%; } .nav-site .nav-site-menu .navbar-nav .nav-item > .dropdown-menu.sm1:after { left: 80.2%; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu.sm2 { left: 44%; padding-right: 20px; min-width: 6rem; } .nav-site .nav-site-menu .navbar-nav .nav-item .dropdown-menu.sm2 .dropdown-item { min-width: 170px; } .nav-site .nav-site-menu .navbar-nav .nav-item > .dropdown-menu.sm2:before { left: 5%; } .nav-site .nav-site-menu .navbar-nav .nav-item > .dropdown-menu.sm2:after { left: 5.2%; } .nav-site .nav-site-menu .navbar-nav .nav-item.dropdown-resources { } .nav-user .user-menu .dropdown-menu { display: block; left: -20px; width: 210px !important; } .nav-user .user-menu .dropdown-menu .dropdown-item { min-width: 170px; } } .card-slider { overflow-x: auto; }

1. All of the following statements are correct with regard to multiple sclerosis (MS), EXCEPT:

A. MS is more common in men than women B. MS is more common in women than men C. MS typically begins between the ages of 20 and 50 D. MS is common in individuals of Northern European Ancestry

2. The clinical signs and symptoms of MS are the result of, which of the following:

A. Depletion of norepinephrine B. Demyelination and damage to neuronal axons C. Damage to ion-gated channels D. Depletion of dopamine

3. Approximately what percentage of individuals with clinically isolated syndrome, who have demyelinating lesions on magnetic resonance imaging (MRI) will develop clinically definite MS?

A. 10% B. 20% C. 88% D. 75%

4. With regard to dalfampridine, which of the following statements is FALSE:

A. It is only available through specialty pharmacies B. It lowers the seizure threshold C. It is U.S. Food and Drug Administration (FDA)-approved to improve walking in patients with MS D. It is FDA-approved to treat relapsing forms of MS

5. Comparative clinical trials suggest that which of the following β-interferon therapies is least efficacious in terms of relapse reduction:

A. Subcutaneous (SQ) interferon β-1b 250 mcg every other day B. SQ interferon β-1a 44 mcg thrice weekly C. SQ interferon β-1a 22 mcg thrice weekly D. Intramuscular (IM) interferon β-1a 30 mcg once weekly

6. Which of the following medications requires patient counseling regarding a postinjection reaction that involves chest tightening, anxiety, and tachycardia:

A. Fingolimod B. Glatiramer acetate C. interferon β-1a D. interferon β-1b

7. All of the following statements are correct regarding teriflunomide, EXCEPT:

A. It is contraindicated in pregnancy B. It requires complete blood count (CBC) and liver function test (LFT) monitoring C. It can remain in the blood for up to 2 years D. It is FDA-approved for the treatment of secondary-progressive MS (SPMS)

8. Which of the following medications has a Risk Evaluation and Mitigation Strategy (REMS) as a result of individuals experiencing bradycardia and atrioventricular (AV) conduction delays:

A. Fingolimod B. Glatiramer acetate C. Dimethyl fumarate D. Dalfampridine

9. Which of the following represents the total lifetime cumulative dose of mitoxantrone for patients with MS:

A. 100 mg/m² B. 140 mg/m² C. 80 mg/m² D. 160 mg/m²

10. Which of the following dosing regimens is correct regarding PEGylated interferon β-1a:

A. It is dosed annually, given intravenously (IV) over 3 to 5 days B. It is dosed every 2 weeks, given as a SQ injection C. It is dosed every 48 hours, given as a SQ injection D. It is dosed every 4 weeks, given as an IV infusion

Evaluation Questions

11. To what extent did the program meet objective #1?

A. Excellent B. Very Good C. Good D. Fair E. Poor

12. To what extent did the program meet objective #2?

A. Excellent B. Very Good C. Good D. Fair E. Poor

13. To what extent did the program meet objective #3?

A. Excellent B. Very Good C. Good D. Fair E. Poor

14. To what extent did the program meet objective #4?

A. Excellent B. Very Good C. Good D. Fair E. Poor

15. Rate the effectiveness of how well the program related to your educational needs:

A. Excellent B. Very Good C. Good D. Fair E. Poor

16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:

A. Excellent B. Very Good C. Good D. Fair E. Poor

17. Rate the quality of the faculty:

A. Excellent B. Very Good C. Good D. Fair E. Poor

18. Rate the effectiveness and the overall usefulness of the material presented:

A. Excellent B. Very Good C. Good D. Fair E. Poor

19. Rate the appropriateness of the examination for this activity:

A. Excellent B. Very Good C. Good D. Fair E. Poor

20. Rate the effectiveness of how well the activity related to your practice needs:

A. Excellent B. Very Good C. Good D. Fair E. Poor

21. Rate the effectiveness of how well the activity will help you improve patient care:

A. Excellent B. Very Good C. Good D. Fair E. Poor

22. Will the information presented cause you to change your practice?

A. Yes B. No

23. Are you committed to making these changes?

A. Yes B. No

24. As a result of this activity, did you learn something new?

A. Yes B. No

25. What is your practice setting or area of practice?

A. Community Pharmacy/Independent B. Community Pharmacy/Chain C. Hospital/Health Systems D. Administrative/Pharmacy Director E. Critical Care Pharmacy F. Long-term Care G. Managed Care/PBM H. Oncology/Specialty Pharmacy I. Industry/Manufacturing

26. How many years have you been in practice?

A. <5 B. 5 – 10 C. 11 – 20 D. >20

« Return to Activity